Difference between revisions of "Pancreatic cancer - historical"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "https://www.thelancet.com/journals/lanonc/article/PII" to "https://doi.org/10.1016/") |
Warner-admin (talk | contribs) m (Text replacement - "https://www.tandfonline.com/doi/abs" to "https://doi.org") |
||
| Line 21: | Line 21: | ||
! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ! style="width: 20%" |[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
| − | |[https:// | + | |[https://doi.org/10.1179/joc.2004.16.6.589 Cantore et al. 2004] |
|1997-2001 | |1997-2001 | ||
| style="background-color:#1a9851" |Phase 3 (E-esc) | | style="background-color:#1a9851" |Phase 3 (E-esc) | ||
| Line 37: | Line 37: | ||
===References=== | ===References=== | ||
| − | #Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. [https:// | + | #Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. [https://doi.org/10.1179/joc.2004.16.6.589 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15700852 PubMed] |
=Metastatic disease, first-line= | =Metastatic disease, first-line= | ||
Revision as of 21:46, 16 September 2022
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main pancreatic cancer page for current regimens.
3 regimens on this page
3 variants on this page
|
Induction therapy for locally advanced disease, unresectable
FLEC
FLEC: Fluorouracil, Leucovorin (Folinic acid), Epirubicin, Carboplatin
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Cantore et al. 2004 | 1997-2001 | Phase 3 (E-esc) | Gemcitabine | Seems to have superior OS |
Chemotherapy
References
- Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M. Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. J Chemother. 2004 Dec;16(6):589-94. link to original article PubMed
Metastatic disease, first-line
PEFG
PEFG: Platinol (Cisplatin), Epirubicin, Fluorouracil, Gemcitabine
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Reni et al. 2005 | 2000-2003 | Phase 3 (E-esc) | Gemcitabine | Seems to have superior PFS |
Chemotherapy
- Cisplatin (Platinol) 40 mg/m2 IV once on day 1
- Epirubicin (Ellence) 40 mg/m2 IV once on day 1
- Fluorouracil (5-FU) 200 mg/m2/day IV continuous infusion over 28 days, started on day 1 (total dose per cycle: 5600 mg/m2)
- Gemcitabine (Gemzar) 600 mg/m2 IV over 60 minutes once per day on days 1 & 8
28-day cycles
References
- Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncol. 2005 Jun;6(6):369-76. link to original article contains dosing details in abstract PubMed
Metastatic disease, all lines of therapy
SMF
SMF: Streptozotocin, Mitomycin, 5-Fluorouracil
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| <965::aid-cncr2820680509>3.0.co;2-2 Kelsen et al. 1991 | 1987-1989 | Phase 3 (C) | CAC | Superior OS |
Chemotherapy
References
- Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991 Sep 1;68(5):965-9. <965::aid-cncr2820680509>3.0.co;2-2 link to original article PubMed